{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:43:37Z","timestamp":1793357017615,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["DK115594"],"award-info":[{"award-number":["DK115594"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["DK128127"],"award-info":[{"award-number":["DK128127"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jhep.2023.01.026","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T20:42:18Z","timestamp":1675456938000},"page":"209-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":149,"title":["Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8393-8410","authenticated-orcid":false,"given":"Alina M.","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2299","authenticated-orcid":false,"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.01.026_bib1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.026_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.026_bib4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib5","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2023.01.026_bib6","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.01.026_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib8","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study","volume":"67","author":"Allen","year":"2018","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib9","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hep4.1510","article-title":"Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the United States","volume":"4","author":"Paik","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.01.026_bib10","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.01.026_bib12","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib13","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/hep.30094","article-title":"Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. Claims database","volume":"68","author":"Allen","year":"2018","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Racila A burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib17","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib19","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib21","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/jgh.15009","article-title":"Nonalcoholic fatty liver disease burden: Australia, 2019-2030","volume":"35","author":"Adams","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib22","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/apt.15673","article-title":"Modelling NAFLD disease burden in four Asian regions-2019-2030","volume":"51","author":"Estes","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.01.026_bib23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A\u00a0global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jhep.2023.01.026_bib24","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/hep.30483","article-title":"The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery","volume":"71","author":"Allen","year":"2020","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5023157","article-title":"The prevalence of NAFLD and fibrosis in bariatric surgery patients and the reliability of noninvasive diagnostic methods","volume":"2020","author":"Soresi","year":"2020","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jhep.2023.01.026_bib26","article-title":"The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States (U.S.)","author":"Younossi","year":"2022","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/liv.14825","article-title":"Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis","volume":"41","author":"Schattenberg","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.01.026_bib28","article-title":"Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study","volume":"2","author":"O'Hara","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.01.026_bib29","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/hepr.13535","article-title":"Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: data from Hong Kong","volume":"50","author":"Tampi","year":"2020","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2023.01.026_bib30","first-page":"504","article-title":"Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States","volume":"32","author":"Adejumo","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.026_bib31","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.cgh.2019.10.023","article-title":"Health care costs of patients with biopsy-confirmed nonalcoholic fatty liver disease are nearly twice those of matched controls","volume":"18","author":"Hagstr\u00f6m","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib32","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.numecd.2020.02.016","article-title":"Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy","volume":"30","author":"Petta","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jhep.2023.01.026_bib33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.21037\/atm-20-7179","article-title":"Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany","volume":"9","author":"Canbay","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jhep.2023.01.026_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100445","article-title":"Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: analysis of a French national hospital database","volume":"25","author":"Boursier","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhep.2023.01.026_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023506","article-title":"Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis (NAFLD\/NASH) patients in Spain","volume":"99","author":"Romero-Gomez","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2023.01.026_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib37","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S2468-1253(22)00020-6","article-title":"Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review","volume":"7","author":"Abeysekera","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2023.01.026_bib38","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.jhepr.2022.100596","article-title":"Real-world evidence on non-invasive tests and associated cut-offs used\u00a0to assess fibrosis in routine clinical practice","volume":"5","author":"Lazarus","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.01.026_bib39","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1007\/s00330-015-3731-2","article-title":"Cost-utility analysis of nonalcoholic steatohepatitis screening","volume":"25","author":"Zhang","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhep.2023.01.026_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015659","article-title":"Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study","volume":"7","author":"Tanajewski","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhep.2023.01.026_bib41","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jhep.2019.08.019","article-title":"Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia","volume":"71","author":"Serra-Burriel","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"Srivastava","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.026_bib43","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1053\/j.gastro.2020.07.050","article-title":"Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis","volume":"159","author":"Noureddin","year":"2020","journal-title":"Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.026_bib44","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.cgh.2020.04.017","article-title":"Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States health care system","volume":"18","author":"Vilar-Gomez","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib45","series-title":"Cost-effectiveness of magnetic resonance elastography for nonalcoholic steatohepatitis fibrosis in the United Kingdom","author":"Kalutkiewicz","year":"2022"},{"key":"10.1016\/j.jhep.2023.01.026_bib46","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","article-title":"Defining comprehensive models of care for NAFLD","volume":"18","author":"Lazarus","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15404","article-title":"Review article Management of NAFLD in primary care settings","author":"Wong","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.01.026_bib48","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the Middle East and north africa: data from global burden of disease 2009-2019","volume":"75","author":"Golabi","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhepr.2019.05.009","article-title":"The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: a real-world patient-reported outcomes study","volume":"1","author":"Balp","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.01.026_bib50","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0140-6736(16)32380-7","article-title":"Socioeconomic status and the 25\u00a0\u00d7 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1\u00b77 million men and women","volume":"389","author":"Stringhini","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.01.026_bib51","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1001\/jama.2016.4226","article-title":"The association between income and life expectancy in the United States, 2001-2014","volume":"315","author":"Chetty","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2023.01.026_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000419","article-title":"Health behaviours, socioeconomic status, and mortality: further analyses of the British Whitehall II and the French GAZEL prospective cohorts","volume":"8","author":"Stringhini","year":"2011","journal-title":"Plos Med"},{"key":"10.1016\/j.jhep.2023.01.026_bib53","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-020-0315-7","article-title":"NAFLD - sounding the alarm on a silent epidemic","volume":"17","author":"Lazarus","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib54","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/hep.32207","article-title":"High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population","volume":"75","author":"Vilar-Gomez","year":"2022","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib55","article-title":"Relationships between socioeconomic status, handgrip strength, and non-alcoholic fatty liver disease in middle-aged adults","volume":"18","author":"Cho","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jhep.2023.01.026_bib56","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep4.1831","article-title":"Community socioeconomic deprivation predicts nonalcoholic steatohepatitis","volume":"6","author":"Giammarino","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.01.026_bib57","first-page":"10","article-title":"What do we know about inequalities in NAFLD distribution and outcomes? A scoping review","author":"Talens","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhep.2023.01.026_bib58","first-page":"91","article-title":"Food insecurity may Be an independent risk factor associated with nonalcoholic fatty liver disease among low-income adults in the United States","volume":"150","author":"Golovaty","year":"2020","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.jhep.2023.01.026_bib59","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/03670244.2021.1875453","article-title":"Food insecurity and lipid profile abnormalities are associated with an increased risk of nonalcoholic fatty liver disease (NAFLD): a case-control study","volume":"60","author":"Tutunchi","year":"2021","journal-title":"Ecol Food Nutr"},{"key":"10.1016\/j.jhep.2023.01.026_bib60","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/ajcn\/nqaa362","article-title":"Food insecurity is associated with magnetic resonance-determined nonalcoholic fatty liver and liver fibrosis in low-income, middle-aged adults with and without HIV","volume":"113","author":"Tamargo","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jhep.2023.01.026_bib61","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jhep.2018.01.015","article-title":"High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance","volume":"68","author":"Zelber-Sagi","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib62","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/hep.31158","article-title":"Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease","volume":"72","author":"Kim","year":"2020","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib63","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MPG.0000000000002527","article-title":"Community socioeconomic deprivation and nonalcoholic fatty liver disease severity","volume":"70","author":"Orkin","year":"2020","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2023.01.026_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/nu12082481","article-title":"A\u00a0snapshot of European children's eating habits: results from the fourth round of the WHO European childhood obesity surveillance initiative (COSI)","volume":"12","author":"Williams","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.jhep.2023.01.026_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.07.021","article-title":"Applying an equity lens to liver health and research in Europe","author":"Ventura-Cots","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib66","unstructured":"Global Burden of Disease (GBD). Institute for Health Metrics and Evaluation (healthdata.org)."},{"key":"10.1016\/j.jhep.2023.01.026_bib67","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.16720","article-title":"A\u00a0sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach","volume":"55","author":"Lazarus","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.01.026_bib68","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.026_bib69","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.28992","article-title":"Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study","volume":"65","author":"Berzigotti","year":"2017","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib70","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/SLA.0b013e31818a01ef","article-title":"Prolonged waiting times for liver transplantation in obese patients","volume":"248","author":"Segev","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2023.01.026_bib71","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.026_bib72","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s11695-015-1727-2","article-title":"A\u00a0systematic review of bariatric surgery in patients with liver cirrhosis","volume":"25","author":"Jan","year":"2015","journal-title":"Obes Surg"},{"key":"10.1016\/j.jhep.2023.01.026_bib73","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2023.01.026_bib74","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0047","article-title":"Cost-effectiveness analysis of bariatric surgery for patients with nonalcoholic steatohepatitis cirrhosis","volume":"2","author":"Klebanoff","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2023.01.026_bib75","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0140-6736(22)01280-6","article-title":"Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial","volume":"400","author":"Abu Dayyeh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.01.026_bib76","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","article-title":"Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis","volume":"19","author":"Bazerbachi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib77","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib78","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/liv.14292","article-title":"Hypothetical treatment of patients with non-alcoholic steatohepatitis: potential impact on important clinical outcomes","volume":"40","author":"Younossi","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.01.026_bib79","first-page":"347","article-title":"Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease","volume":"25","author":"Rustgi","year":"2022","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jhep.2023.01.026_bib80","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S2213-8587(15)00519-7","article-title":"The rising cost of diabetes care in the USA","volume":"4","author":"Peter","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jhep.2023.01.026_bib81","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","article-title":"Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association","volume":"123","author":"Heidenreich","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2023.01.026_bib82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.01.026_bib83","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib84","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(11)60702-2","article-title":"Towards an improved investment approach for an effective response to HIV\/AIDS","volume":"377","author":"Schwartl\u00e4nder","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.01.026_bib85","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.26633\/RPSP.2018.62","article-title":"Development of an investment case for obesity prevention and control: perspectives on methodological advancement and evidence","volume":"42","author":"Milliken","year":"2018","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.jhep.2023.01.026_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph15030522","article-title":"A\u00a0review of the impacts of different approaches for diabetes prevention and a framework for making investment decisions","volume":"15","author":"Alva","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jhep.2023.01.026_bib87","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jhep.2020.09.013","article-title":"A\u00a0global investment framework for the elimination of hepatitis B","volume":"74","author":"Howell","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib88","series-title":"Eliminating viral hepatitis: the investment case. Doha","author":"Pedrana","year":"2018"},{"key":"10.1016\/j.jhep.2023.01.026_bib89","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S2468-1253(20)30010-8","article-title":"Global hepatitis C elimination: an investment framework","volume":"5","author":"Pedrana","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.026_bib90","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S2468-1253(20)30008-X","article-title":"A\u00a0model of the economic benefits of global hepatitis C elimination: an investment case","volume":"5","author":"Scott","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2023.01.026_bib91","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782300079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782300079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:49:44Z","timestamp":1759175384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882782300079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S016882782300079X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.01.026","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}